



**Vaccicure Limited**  
Registered office and principal place of business  
Floor 9, The Royal Liver Building  
Pier Head  
Liverpool L3 1JH  
England

FOR IMMEDIATE RELEASE

## **New Directors added to Board of Vaccicure Limited**

**Liverpool, England, U.K., October 7, 2016**— [Vaccicure Limited](#), the company set up to fund the clinical trials of the Polyclonal Antibody Stimulator (PAS) developed by [Cancer Advances Inc.](#), is pleased to announce the addition of three new, independent directors; Arthur Fowle, Lee McCracken, and Warren Stern. The announcement of these new board members will strengthen the foundation and mission of Vaccicure in funding Cancer Advances clinical trials.

The newly appointed Board Members are:

### **Dr Arthur Fowle FRCP**

Dr Fowle trained at King's College Hospital, London, intending to practise cardiology. He joined Wellcome Research Laboratories, Beckenham, in 1965 as a clinical physiologist. Security of tenure was promised if he became a part-time consultant physician in the NHS. In the interval, clinical pharmacology was formally recognized as the discipline which he practised. He became head of the clinical pharmacology department in 1968 and part-time consultant general physician in the same year. He retired from Wellcome in 1992. Dr Fowle is an expert in the conduct of clinical trials.

### **Lee McCracken, M.Sc., MBA**

Lee McCracken is Chairman of Global Medical and Research Technologies since May 2016 following his appointment as a Director in 2015. Global Medical is developing novel solutions for Organ Transplantation, Immuno-Oncology, and Regenerative Medicine. Previously, he was CEO of Gensignia Life Sciences, a miRNA-digital information technology company focused on proprietary blood-based tests for the early detection of lung cancer, from 2014 to 2016. Mr. McCracken is an executive leader whose background spans start-ups to commercial organizations with significant revenues. In addition, he has substantial transactions experience in the diagnostic and pharmaceutical sectors, plus venture capital experience.

Mr. McCracken has also served as President & CEO of Pathwork Diagnostics, a venture capital backed company that developed and commercialized an FDA-cleared diagnostic for difficult to diagnose cancers, which was acquired by Response Genetics in 2013. Previously, he served as Corporate Head of Business Development at Prometheus Laboratories, a leading personalized medicine company with diagnostic and pharmaceutical products in gastroenterology and oncology, which grew to over \$500 million in sales prior to its acquisition by Nestle Health Science in 2011.



## **Vaccicure Limited**

Registered office and principal place of business  
Floor 9, The Royal Liver Building  
Pier Head  
Liverpool L3 1JH  
England

Earlier, Mr. McCracken was SVP Pharmaceutical Business Development of Diversa Corporation a genomic technology company which was merged into Verenum, President & CBO of GenStar Therapeutics, a pre-clinical gene therapy company which merged into Corautus, SVP Corporate Development at CombiChem, a venture capital backed company acquired by DuPont Pharmaceuticals, and Director Business Development / Managing Director at Allergan / Pacific Pharma. Mr. McCracken also held positions in the venture capital industry with Union Venture and 3i Capital (a US subsidiary of 3i Group plc). Mr. McCracken received a B.S. from Santa Clara University, an M.Sc. in Computer Science from the University of Dayton and an M.B.A. from Anderson School of Management at UCLA.

### **Warren Stern PhD**

Dr Stern is the owner of Stern Drug Development, LLC and has more than 30 years of pharmaceutical product development experience in a wide variety of therapeutic areas and drug delivery systems, including preclinical (pharmacology, ADME, formulation development, toxicology) and clinical research in early stage companies. This includes pre-Registered Office: 9th Floor, The Royal Liver Building, Pier Head, Liverpool. L3 1JH Registered in England & Wales No. 08988870 IND to IND filings for pharma and contract research organizations, first in man clinical trials, coordination of complex multicenter phase II-III clinical studies and IND/NDA/sNDA submissions. Areas of expertise include preclinical and clinical testing of drugs for sickle cell disease, analgesic drugs, psychiatric and neurological disorders, hypoxia and SpO2 measures, asthma, obesity, bone metabolism, stroke and other therapeutic areas, oral and parenteral drug delivery systems, regulatory considerations, intellectual property strategy, commercial relationships with pharmaceutical companies and government agencies. Holds more than 10 issued and pending pharmaceutical use-patents, including applications related to: a method of determining risk of experiencing a hypoxic episode in subjects receiving opioid medications; and for a method of enhancing the action of 5-HMF in improving blood oxygenation.

Entrepreneurial experience includes CEO/President position at a publicly held early stage drug delivery company (Pharmatec), co-founding of Research Triangle Pharmaceuticals (a subsidiary of Cato Holdings; acquired by SkyePharma) and co-founding of Nobex Corp. (acquired by Biocon). He was also the SVP of Drug Development and an investor in AesRx LLC (acquired by Baxter). Major pharma experience for 12 years included Head of Clinical Neuroscience at Burroughs Wellcome Company and Senior Vice President of Clinical Research at Forest Laboratories.

In respect to education, Dr Stern received a B.S. from City University of New York (Brooklyn College) in 1965, a PhD from Indiana University, Ph.D., in Psychopharmacology in 1969, and held Post-Doctoral Fellowships in Neurophysiology—Boston State Hospital 1970-1971 and Neuropharmacology—Worcester Foundation for Experimental Biology, 1971-1972.



**Vaccicure Limited**  
Registered office and principal place of business  
Floor 9, The Royal Liver Building  
Pier Head  
Liverpool L3 1JH  
England

### **About Vaccicure Limited**

7th July 2015 marks the launch of the Vaccicure investment opportunity. [Vaccicure Limited](#), the company set up to fund the clinical trials of the Polyclonal Antibody Stimulator (PAS) developed by Cancer Advances Inc., has now produced the final Information Memorandum that will be made available to qualifying investors from 7th July. Funding is through the purchase of Redeemable Preference Shares. The opportunity is only available to high net worth investors, sophisticated investors and investment professionals. For more information about investing contact the [Keyholder Funding Team](#).

### **About Cancer Advances Inc.**

Cancer Advances Inc., a wholly owned subsidiary of Cato Holding Company, is a biotechnology company focused on impacting human health and suppressing the progression of gastrointestinal cancers by enhancing the adaptive immune system. The company is led by an experienced management team and has a broad intellectual property portfolio.

**Please visit our product page for more information on what is in development:**

<http://www.canceradvancesinc.com/product.html>

Contact: John Wingen

Chief Financial Officer, [Vaccicure Limited](#)

Phone: 1-919-361-1229 [Click Here to Email](#)